BioNTech Deal Shows Pfizer Is Reinvesting COVID-19 Windfall In mRNA

 
• By Alaric DeArment

The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.

Businessman touched r and d sign. R d icon network business concept word cloud background tag. R&D: Research and development word lettering typography design illustration with line icons and ornaments
Pfizer and BioNTech announced their third vaccine deal, for an mRNA shingles vaccine • Source: Shutterstock

More from Anti-infective

More from Therapy Areas